Answers are grounded in this paper and cite their sources.
Prostate-specific antigen screening has a low positive predictive value in low-incidence populations, leading to unnecessary biopsies. In this study, we developed and validated a prostate cancer prediction model incorporating transrectal ultrasound features and prostate-specific antigen density stratification and evaluated its cost-effectiveness. This dual-center retrospective study included 767 men with prostate-specific antigen levels of ≥4 ng ml-1 (training cohort, n = 558; validation cohort, n = 209). Prostate-specific antigen density was stratified into five categories. A logistic regression model was developed and validated. The cost-effectiveness of four screening strategies was evaluated. Five independent predictors were identified: age, prostate-specific antigen density stratification, extraprostatic extension, solid hypoechoic lesions, and unclear boundary. The model showed good discrimination (0.915 and 0.943 in the training and validation cohorts, respectively) and calibration (Hosmer-Lemeshow P = 0.57). The high-threshold strategy (≥0.5) avoided 47.0% of biopsies, and had the lowest total cost. In the biopsy cohort, the cost per cancer detected was the lowest in men with prostate-specific antigen density ≥0.15 ng ml-2 (83 295 Chinese Yuan). This model can reduce unnecessary biopsies in men with elevated prostate-specific antigen levels identified from opportunistic testing, but it is not suitable for population-wide screening given its unfavorable cost-effectiveness. It provides incremental value in resource-limited settings rather than serves as a practice-changing alternative to contemporary magnetic resonance imaging (MRI)-based pathways.
No takes yet. Share an insight, caveat, or question.
Liang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: